Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marshall Bedine

Gastroenterology Lutherville, MD Medical Doctor

NPI 1194719658 CMS profile 1301289

10751 Falls Rd, Suite 301, Lutherville, MD 21093

Open in the dashboard

General payments

$8,009

405 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marshall Bedine of Lutherville, MD is reported in the CMS Open Payments database as having received $8,009 across 405 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,027 100
2024 General $2,024 95
2023 General $1,816 93
2022 General $1,097 59
2021 General $446 23
2020 General $288 17
2019 General $310 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marshall Bedine
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Marshall Bedine were reported at $2,027. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Marshall Bedine Gastroenterology median Middle half National median
2019 $310 $417 $126–$1,100 $163
2020 $288 $224 $74–$624 $114
2021 $446 $352 $106–$1,054 $132
2022 $1,097 $448 $129–$1,270 $149
2023 $1,816 $533 $150–$1,390 $160
2024 $2,024 $605 $160–$1,606 $164
2025 $2,027 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,666 157 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,279 50 payments
  3. Pfizer Inc. $691 37 payments
  4. Janssen Biotech, Inc. $560 31 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $398 19 payments
  6. Braintree Laboratories, Inc. $367 13 payments
  7. Daiichi Sankyo Inc. $235 10 payments
  8. Celgene Corporation $212 11 payments
  9. Celltrion USA Inc. $114 6 payments
  10. Ipsen Biopharmaceuticals, Inc $111 5 payments
  11. Other $1,376 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,708 397 payments
  2. Gift $280 4 payments
  3. Education $20 4 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $1,206 45 payments
  2. RINVOQ $1,029 65 payments
  3. LINZESS $792 44 payments
  4. CREON $771 41 payments
  5. XELJANZ $592 32 payments
  6. STELARA $500 28 payments
  7. SKYRIZI $470 28 payments
  8. VIBERZI $428 21 payments
  9. XIFAXAN $369 17 payments
  10. VELSIPITY $352 19 payments
  11. Other $3,494 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

674

Median for Gastroenterology: 569

Drug cost

$172,176

Median for Gastroenterology: $104,976

Branded share of claims

20.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $86,660
Mesalamine Generic 38 $25,525
Linzess Linaclotide Brand 24 $22,487
Mesalamine Dr Mesalamine Brand 14 $9,099
Mesalamine Er Mesalamine Brand 20 $5,814
Esomeprazole Magnesium Generic 88 $4,974
Famotidine Generic 48 $3,800
Pantoprazole Sodium Generic 106 $2,556
Budesonide Dr Budesonide Brand 20 $2,395
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 17 $1,971

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$854,976

Of which drugs: $753,353

Medicare patients

828

Average age 74

Services billed

53,635

532 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 54%
Osteoporosis 35%
Ischemic heart disease 29%
Diabetes 22%
Depression 22%
Cancer 21%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 23 21,900 $376,078
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 19 3,260 $80,901
Injection, denosumab, 1 mg J0897 Office 33 2,520 $51,239
Injection, zoledronic acid, 1 mg J3489 Office 75 375 $1,809

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $383
$383 — 21,900
SKYRIZI
  • AbbVie, Inc. $241
$241 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $146
$146 — —
RINVOQ
  • AbbVie, Inc. $134
$134 — —
STELARA
  • Janssen Biotech, Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

405 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record